Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
I have an aortic aneurism. Echocardiograms in 2021 and 2022 measured my ascending aorta at 4.6 centimeters. Though I have not been formally diagnosed with Marfan’s Syndrome, Marfan’s Syndrome runs in my family and I consider myself to be “Marfan-like.”
To complicate my health, I developed a late stage side effect called chemotherapy-induced cardiomyopathy in late 2015. I am a long-term cancer survivor and aggressive high dose, cardiotoxic chemo damaged my heart.
When the ascending aorta becomes enlarged (usually considered an aneurism when it reaches a diameter of over 5 centimeters), there are risks and benefits associated with surgical intervention. It is these risks and benefits that I struggle with when thinking about my own aortic aneurism and whether to fix it surgically.
Benefits of Surgical Intervention:
Risks of Surgical Intervention:
Ultimately, the decision to undergo surgery for an enlarged ascending aorta is complex and should be made in consultation with a healthcare team that is familiar with the specific details of the patient’s case. They will consider factors such as the size and location of the aneurysm, the patient’s overall health, and any other individual considerations. It’s important for patients to discuss their concerns and ask any questions they may have with their healthcare provider.
Full disclosure- conventional oncology screwed up my my cancer treatment and I am highly skeptical of all conventional medical professionals.
What do you think? Should I undergo surgery to fix my aortic aneurysm or wait and see? Let me know-
David Emerson
“There are no evidence based guidelines for the surveillance of patients with moderate-sized (<5 cm) thoracic aortic aneurysms (MTAA), who do not warrant surgical intervention…
Thoracic aortic aneurysms account for almost 50,000 deaths annually in the United States [1]. Death is due to rupture or dissection and is strongly linked to the size of the aneurysm [2]. Recent Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease represent the efforts of multiple professional societies (ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM) to develop evidence based recommendations for the management of all aspects of thoracic aortic disease in order to improve patient outcomes [3]…
Current guidelines recommend surgical intervention for ascending thoracic aortic aneurysms when they are 5 cm in size for patients with genetic predisposition to rupture/dissection such as the connective tissue disorder Marfan’s syndrome, or 5.5 cm in size for non-Marfan patients [3].
Similarly the recommendations are to surgically intervene when a descending thoracic aortic aneurysm is 5.5 cm for a Marfan or 6 cm for a non-Marfan patient [2–6]. These guidelines are based on data showing increased mortality for these patients. Thus, the risk of rupture-related complication exceeds the risk of surgery-related complications for this high risk patient sub-group – rendering an operation as the safer strategy…
Patients were considered to have met the study’s primary adverse composite end point if one of the following outcomes occurred at any point in time during the follow up:
Due to accuracy and ready accessibility, CT scans have traditionally been the diagnostic test of choice to measure aneurysm size. For our patient population, therefore, changes over time in serial CT images were used to evaluate the achievement of the primary study endpoints.
Based on visual inspection, a natural cut point in the data appeared to be located around 4.3 cm. A negative likelihood ratio analysis (NLR) was used to validate this cut point; the smallest NLR was achieved using ≥ 4.3 cm as the threshold measure to differentiate “at-risk” versus “not-at-risk” patients for an adverse, composite event…
Aortic aneurism are of concern because of their potential risk of death. The likelihood of a mortal event occurring has been linked historically to aneurysm size. Elegant natural history studies from the 70s and 80s demonstrated a significant increased incidence of mortality at size greater than 6 cm for the ascending aorta and 7 cm for the descending aorta…
However even with a smaller diameter there is still a risk of complication. Thus even for MTAA patients with an initial aneurysm size of 4–4.9 cm, there is 5 – 10% yearly risk of rupture, dissection or death [12]. To-date, the sub-group of these MTAA patients at highest risk for a future adverse event has not been well established…
While cheaper, safer, and more readily accessible, echocardiography appears to be a less reliable approach to document aneurism size, as the echo findings may be (at least, in part) operator dependent [7]. Moreover, aneurysms of the arch and descending thoracic aorta cannot be accurately followed using an echo-based surveillance strategy, making the use of echo as the sole method of measurement of aortic size controversial…